Case Summary: BioXcel Therapeutics Chapter 11
BioXcel Therapeutics filed for Chapter 11 after its sole approved product, IGALMI, never reached commercial scale and revenue could not support roughly $112 million of secured debt, pursuing a 363 sale to stalking horse Teva for $57.5 million cash plus up to $67.5 million in milestone payments.